BMX-001 by Biomimetix JV for Oropharyngeal Cancer: Likelihood of Approval
BMX-001 is under clinical development by Biomimetix JV and currently in Phase II for Oropharyngeal Cancer.
Source: pharmaceutical-technology.com
Page 8 - Pharmaceutical Intelligence News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Pharmaceutical Intelligence. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Pharmaceutical Intelligence Today - Breaking & Trending Today
Futibatinib by Otsuka Pharmaceutical for Extrahepatic Bile Duct Cancer: Likelihood of Approval
Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Extrahepatic Bile Duct Cancer.
Source: pharmaceutical-technology.com
XTX-202 by Xilio Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
XTX-202 is under clinical development by Xilio Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer.
Source: pharmaceutical-technology.com
Duvelisib by Secura Bio for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Duvelisib is under clinical development by Secura Bio and currently in Phase II for Nodal Marginal Zone B-Cell Lymphoma.
Source: pharmaceutical-technology.com
TC-510 by TCR2 Therapeutics for Malignant Pleural Mesothelioma: Likelihood of Approval
TC-510 is under clinical development by TCR2 Therapeutics and currently in Phase II for Malignant Pleural Mesothelioma.
Source: pharmaceutical-technology.com